Mechanism of Impaired NLRP3 Inflammasome Priming by Monophosphoryl Lipid A
- 3 May 2011
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 4 (171), ra28
- https://doi.org/10.1126/scisignal.2001486
Abstract
Monophosphoryl lipid A (MLA), a nontoxic derivative of the endotoxin lipopolysaccharide (LPS), has been approved in the United States for use as a vaccine adjuvant. LPS and MLA are ligands of Toll-like receptor 4 (TLR4), and it has been unclear why LPS triggers toxic inflammation, whereas MLA generates safe and effective immunostimulation. Signaling downstream of TLR4 is mediated by the adaptor proteins TRIF [Toll–interleukin-1 (IL-1) receptor (TIR) domain–containing adaptor-inducing interferon-β], which is required for adaptive immune outcomes, and MyD88 (myeloid differentiation marker 88), which is responsible for many proinflammatory effects. Two models have provided nonexclusive explanations for the differential effects of LPS and MLA. According to the first model, MLA fails to induce maturation of the proinflammatory cytokine IL-1β because it fails to activate caspase-1, which is required for the conversion of pro–IL-1β into its bioactive form. The second model suggests that MLA triggers unequal engagement of both of the signaling adaptor pathways of TLR4, such that signaling mediated by TRIF is largely intact, whereas signaling mediated by MyD88 is incomplete. We show that the TRIF-biased signaling that is characteristic of low-toxicity MLA explains its failure to activate caspase-1. Defective induction of NLRP3, which depends on MyD88, led to decreased assembly of components of the IL-1β–activating inflammasome required for the activation of preformed, inactive procaspase-1. In addition, we elucidated the contributions of MyD88 and TRIF to priming of the NLRP3 inflammasome and demonstrated that TRIF-biased TLR4 activation by MLA was responsible for the defective production of mature IL-1β.Keywords
This publication has 60 references indexed in Scilit:
- Activation of the NLRP3 inflammasome by intracellular poly I:CFEBS Letters, 2010
- Modulation of Inflammasome Activity for the Treatment of Auto-inflammatory DisordersJournal of Clinical Immunology, 2010
- Selective Activation of the p38 MAPK Pathway by Synthetic Monophosphoryl Lipid APublished by Elsevier BV ,2009
- The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot studyAnnals Of The Rheumatic Diseases, 2009
- Cutting Edge: TNF-α Mediates Sensitization to ATP and Silica via the NLRP3 Inflammasome in the Absence of Microbial StimulationPublished by The American Association of Immunologists ,2009
- The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesisNature Immunology, 2009
- The Nlrp3 inflammasome is critical for aluminium hydroxide‐mediated IL‐1β secretion but dispensable for adjuvant activityEuropean Journal of Immunology, 2008
- A NOD2–NALP1 complex mediates caspase-1-dependent IL-1β secretion in response to Bacillus anthracis infection and muramyl dipeptideProceedings of the National Academy of Sciences of the United States of America, 2008
- The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activationCell Death & Differentiation, 2007
- A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytesNature, 1992